Destiny Pharma
plc
("Destiny
Pharma" or the "Company")
Exercise of Options and Total
Voting Rights
Brighton, United Kingdom - 19 March
2024 -
Destiny Pharma (AIM: DEST), a clinical
stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life
threatening infections, announces that it has
issued and allotted 40,000 new ordinary shares of 1
pence each in the capital of the Company (the "New Ordinary
Shares") following an exercise of share options by a former
employee.
Application will be made to the
London Stock Exchange for the New Ordinary Shares to be admitted to
trading on AIM, with dealings expected to commence on 25 March 2024
("Admission").
Following Admission, the Company
will have a total of 95,311,863 Ordinary Shares in issue.
Shareholders may use this figure of 95,311,863 Ordinary Shares as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
- END -
For
further information, please contact:
Destiny Pharma plc
Chris
Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI
Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative,
clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development
pipeline includes two late stage assets NTCD-M3, a microbiome-based
biotherapeutic for the prevention of C.
difficile infection (CDI)
recurrence which is the leading cause of hospital acquired
infection in the US, and XF-73 nasal gel, a proprietary drug
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA.
For further information on the
company, please visit www.destinypharma.com